Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Metastatic Solid Tumors 1Cholangiocarcinoma 1Camurati-Engelmann Syndrome 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cisplatin 27pembrolizumab 21Brachytherapy 16Radiotherapy 14Carboplatin 10Radiation 8Paclitaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Topotecan 6fludarabine 5atezolizumab 5Magnetic Resonance Spectroscopy 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Nivolumab 4Gemcitabine 4tremelimumab 3temsirolimus 3human papillomavirus vaccine, L1 type 16, 18 3aldesleukin 3Radiotherapy, Intensity-Modulated 3Papillomavirus Vaccines 3Ipilimumab 3Interleukin-2 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Docetaxel 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uterine Cervical Neoplasms × bintrafusp alfa protein, human × Clear all
NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

EMD Serono

Phase 1 Completed
25 enrolled 14 charts
Gynecologic

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡